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Abstract
Macrophages can remove antigen from the surface of antibody-coated cells by a process termed trogocytosis. Using live cell
microscopy and flow cytometry, we investigated the dynamics of trogocytosis by RAW264.7 macrophages of Ramos B cells
opsonized with the anti-CD20 monoclonal antibody rituximab. Spontaneous and reversible formation of uropods was
observed on Ramos cells, and these showed a strong enrichment in rituximab binding. RAW-Ramos conjugate interfaces
were highly enriched in rituximab, and transfer of rituximab to the RAW cells in submicron-sized puncta occurred shortly
after cell contact. Membrane from the target cells was concomitantly transferred along with rituximab to a variable extent.
We established a flow cytometry-based approach to follow the kinetics of transfer and internalization of rituximab.
Disruption of actin polymerization nearly eliminated transfer, while blocking phosphatidylinositol 3-kinase activity only
resulted in a delay in its acquisition. Inhibition of Src family kinase activity both slowed acquisition and reduced the extent
of trogocytosis. The effects of inhibiting these kinases are likely due to their role in efficient formation of cell-cell conjugates.
Selective pre-treatment of Ramos cells with phenylarsine oxide blocked uropod formation, reduced enrichment of rituximab
at cell-cell interfaces, and reduced the efficiency of trogocytic transfer of rituximab. Our findings highlight that dynamic
changes in target cell shape and surface distribution of antigen may significantly influence the progression and extent of
trogocytosis. Understanding the mechanistic determinants of macrophage trogocytosis will be important for optimal design
of antibody therapies.
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Introduction
Fcc receptors (FccR) expressed on phagocytic cells such as
macrophages and neutrophils play an important role in mediating
the clearance of IgG-opsonized foreign material from the body.
FccR can mediate several mechanistically distinct uptake process-
es. Large (.1 mm diameter) particles can be taken up by phagocy-
tosis, where directed rearrangement of the actin cytoskeleton
generates pseudopods that engulf the particle [1]. In contrast,
small soluble immune complexes are internalized through
clathrin-mediated endocytosis, where clathrin-coated pits pinch
off from the plasma membrane to form endosomes. These two
routes of internalization make use of different mechanisms and
have different signalling requirements [2–4]. A distinct third
situation is that in which the antibody is neither in a soluble
complex nor bound to a rigid particle, but rather is bound to an
antigen on the surface of a cell. In this case, though targeted
antigen is confined to the target cell membrane, it is potentially
mobile within the plane of that membrane, adding an additional
level of complexity.
The term trogocytosis was coined to describe the phenomenon
where surface molecules are extracted from one cell by another
[5]. Many groups have demonstrated the ability of lymphocytes to
trogocytose through their antigen receptors. T cells are able to
acquire cognate MHC-peptide and associated membrane via their
TCR [6]; this acquisition may be involved in the termination of
the T cell response by conferring specificity to regulatory T cells
[7], or by sensitizing antigen-specific T cells to fratricidal CTL-
mediated killing [8]. B cells can internalize membrane-bound
antigens via their B cell receptors, directing the antigens to MHC-
loading compartments for subsequent presentation to T cells [9].
NK cells are able to acquire activatory ligands for NK receptors,
thus becoming able to modulate the activity of other NK cells in
trans [10]. These examples of trogocytosis occur at organized cell-
cell interfaces, often termed immunological synapses.
Trogocytosis has also been studied in the context of FccR-
bearing macrophages removing surface antigen from IgG-
opsonized cells. While this phenomenon was first observed over
three decades ago in early studies of phagocytosis [11], it has only
recently been studied in detail, in particular within the context of
cells opsonized with the therapeutic anti-CD20 antibody ritux-
imab (RTX), as well as several other therapeutic antibodies
[12–14]. RTX is useful clinically because of its ability to promote
the clearance of CD20-expressing B lymphoma cells. Taylor and
coworkers have demonstrated that both RTX and CD20 are
removed from RTX-opsonized B cells by trogocytosis in vitro [12]
and in vivo [15]. This is of substantial clinical significance, as the
removal of CD20 limits the therapeutic efficacy of RTX by
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mechanisms of antibody-dependent cellular cytotoxicity, comple-
ment-dependent cytotoxicity, phagocytosis, or the induction of
apoptosis [16]. Given the rapidly increasing role of therapeutic
antibodies in medicine [17], a greater understanding of the factors
that influence macrophage trogocytosis will be important for
improved design of such therapies.
While FccR-mediated trogocytosis has been previously demon-
strated by several groups, the dynamics of this process – how
macrophages and target cells interact in real time - has been little
explored. We sought to better understand these dynamics by
following the process using live cell microscopy. For FccR-bearing
cells we used RAW264.7 cells, a mouse macrophage cell line that
has been used extensively for studying FccR-mediated phagocy-
tosis. As the trogocytic target, we used cells of the Ramos B
lymphoma cell line, opsonized with RTX. We hypothesize that
target cells may not simply be passive players in trogocytosis.
Indeed, we find that trogocytosis is a highly dynamic process in
which rearrangements of ligand on the opsonized target cell can
play an active role.
Results
Dynamic morphology of Ramos cells and trogocyte
capture of RTX-rich uropodia
We sought to follow the progression of trogocytosis by
examining the interaction of opsonized Ramos cells with adherent
RAW cells by time lapse fluorescence microscopy. Notably, it was
immediately apparent that even in the absence of interaction with
a phagocytic (or ‘‘trogocytic’’) cell, the distribution of Alexa Fluor
488-labeled RTX (RTX-Al488) on the opsonized Ramos cells was
not uniform. The Ramos cells were motile, and alternated
between displaying a round morphology and fluctuating mor-
phology with extensive lamellipodia (Figure 1, top row). This
behaviour was independent of RTX opsonization (data not
shown). While RTX was homogenously distributed on the surface
of round cells, on cells with lamellipodia the RTX-Al488 signal
became strikingly polarized to the end of the cell opposite the
lamellipodial extensions (Figure 1, middle row). In most cases cells
‘‘squirmed’’ in one location with a CD20-positive uropod adherent
to the substratum, while in others, Ramos cells moved over
extended distances, with RTX concentrating at the back end of
the cell (Videos S1 and S2). Polarized localization of CD20/RTX
was robust; at any given moment in time, 1263% of Ramos cells
displayed a polarized morphology, and 8461% of these cells
showed polarization of RTX to the end of the cell opposite
lamellipodial extensions (6 s.d., n=4 experiments, with .300
cells scored/experiment). This polarization of RTX was rapidly
reversible; a return to the round morphology was accompanied by
the homogenous redistribution of RTX.
This non-uniform distribution of CD20 clearly has important
implications for the interaction of opsonized Ramos with RAW
cells. Of note, RAW cells formed conjugates with Ramos in which
striking concentration of RTX was seen at the cell-cell interface
(Figures 2A and 2B). Prior polarization of CD20 may favour
trogocytosis by concentrating antigen in one location. Indeed, on
occasion, RAW cells appeared to capture polarized Ramos by
binding to the RTX-positive end (Figure 2C, Videos S3 and S4).
RAW cells were able to interact with multiple Ramos cells at once;
Video S5 shows a RAW cell with several bound motile Ramos, in
each of which RTX-Al488 is concentrated at the cell-cell interface.
Capture of Ramos via a pre-existing RTX-enriched polarized end
provides one possible explanation for the observed concentration
of RTX at interfaces; it is also possible, however, that Ramos
polarization occurs concurrently with or subsequent to binding to
the RAW cells. Alternatively, forces exerted by the RAW cells via
their FcR may drive the local clustering of RTX. These
possibilities are not mutually exclusive; both cells may contribute
in a concerted fashion to forming a concentrated zone of RTX.
Since the changes in Ramos morphology are rapid and reversible,
Figure 1. Dynamic morphology of Ramos B cells. Selected frames from live microscopic imaging of RTX-Al488 coated Ramos cells (Video S1).
Ramos cells were able to adhere to the substratum by the formation of a uropod as seen at the first time of observation (0 min), and at 10 and 15
minutes afterwards. RTX-Al488 (green) was enriched at uropods, while being depleted from the opposite, mobile end. Scale bar 10 mm.
doi:10.1371/journal.pone.0014498.g001
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the respective roles of trogocyte and target cell in forming this
enriched contact zone. To address the question of what effect
Ramos-driven polarization of CD20 has on the trogocytic
interaction, we sought to prevent this polarization by pharmaco-
logical inhibition. We first attempted to use cholesterol extraction
of the Ramos cells with methyl-b-cyclodextrin to disrupt
membrane microdomains,which may contribute to the subcellular
localization of RTX [18]. Moderate extraction conditions (10 mM
methyl-b-cyclodextrin for 10 min) did not abolish uropod
formation. More prolonged treatment (30 min) did have an
inhibitory effect; however, it also resulted in a ten-fold decrease in
the extent of RTX opsonisation, suggesting that extensive
cholesterol depletion prevents efficient RTX binding to CD20
(data not shown). As an alternative approach, we tried pretreating
Ramos cells with the phosphatase inhibitor phenylarsine oxide
(PAO) to promote a general disruption of signalling pathways. We
found that treatment with PAO led to a loss of cell motility and
uropod formation that was irreversible over the time scale of our
experiments (Figure 3A, B). This allowed us to treat Ramos cells
with PAO, then wash away the PAO and examine the interaction
of the pretreated Ramos with RAW cells. We observed that
concentration of RTX at cell-cell interfaces was substantially
reduced by pre-treatment of Ramos with PAO (Figure 3C). This
suggests that polarization of the target cell contributes to the
localized accumulation of RTX at cell-cell interfaces.
Internalization of RTX-Al488 by RAW cells
Within minutes of capture, small sub-micron RTX-Al488
positive puncta became visible moving inside the RAW cells near
the site of contact (Videos S3 and S4). Over longer times, these
became widely distributed throughout the RAW cells (Figure 4),
where they appeared to stream in a directed manner (Video S6).
At late times, RTX-Al488 was found in large vacuolar
compartments in many cells (Video S7).
RTX-dependent transfer of target cell membrane to
trogocyte
It has been demonstrated in previous studies of trogocytosis
using RTX-opsonized targets that not only antibody, but also
CD20 and accompanying fragments of target cell membrane are
transferred to the trogocyte [12,13]. To confirm similar transfer in
our system, we labelled Ramos cells with the membrane dye
PKH26 before opsonization. By flow cytometry, we observed that
PKH26 is indeed transferred from the Ramos to RAW cells
(Figure 5A). Interestingly, PKH26 acquisition was not directly
proportional to RTX transfer throughout the trogocytic reaction
(Figure 5A). Early during trogocytosis, it appears that more RTX
is transferred per amount of bulk membrane. The enrichment of
RTX at interfaces may initially favour either transfer of RTX/
CD20 complexes with less accompanying membrane, or enhanced
transfer of RTX alone. Observation of RTX-Al488 positive
compartments in RAW cells after trogocytosis by microscopy
similarly revealed heterogeneity in the extent of co-transfer of
PKH26; in some cells, there was significant PKH26 label in all
compartments that had RTX, whereas in others, relatively little
concomitant PKH26 transfer was seen (Figure 5C). Transfer of
PKH26 was dependent on RTX opsonization of Ramos cells
(Figure 5B); also, both RTX and PKH26 were acquired directly
from the target cell rather than through passive transfer by release
into the medium, as no transfer of either label was seen when
RAWs were incubated for 45 min with culture supernatants from
RTX/PKH26 labelled Ramos cells that had been incubated for
45 min to allow for possible release of label (Figure 5B).
Figure 2. Concentration of RTX at RAW-Ramos interfaces. (A)
Volumetric reconstruction from confocal slices of a Ramos-RAW cell
interface. RTX-Al488-coated (green), PKH26-labelled Ramos cells (red)
were incubated with RAW cells for 45 minutes at 37uC. RAW cells were
labelled with anti-CD11b-APC (cyan). The RAW cell has extensively
trogocytosed both RTX and PKH26. Inset shows the dotted area above
it without the PKH26 channel overlaid, revealing the concentration of
RTX-Al488 at the cell-cell interface, otherwise depleted from the rest of
the Ramos cell. Trogocytosis reaction was halted by fixation 45 min
after co-incubation. Ramos cells are approximately 12 mm in diameter.
(B) Deconvolved epifluorescence images from live experiment of
PKH26-labelled, RTX-Al488 coated Ramos after coincubation with
RAW cells for 1 hour. Extended focus and volumetric representations
of the imaged slices show accumulation of RTX-Al488 at the interface.
Scale bar 5 mm. Unit size for volume 3.3 mm. (C) Frames from live
microscopic imaging following a RTX-Al488 coated Ramos cell settling
onto a RAW macrophage. Extensive RAW membrane ruffling occurs to
capture the uropod (black arrow, 9 minutes), and RTX is internalized
shortly after (white arrow, 13.5 minutes). See Video S3. Scale bar 10 mm.
doi:10.1371/journal.pone.0014498.g002
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cells
It is clear from microscopy that the RTX is not only transferred
to the RAW cell but becomes internalized, as was also seen in
earlier studies of macrophage trogocytosis [12]. We wanted to
analyze this process by flow cytometry and differentiate between
internalized and surface-exposed RTX over time. To this end, we
incorporated labelling of surface-exposed RTX on RAW cells with
anti-human antibodies (recognizing the Fc portion of this chimeric
antibody). After incubation together, RAW cells were washed,
detached, and then distinguished from remaining Ramos cells by
staining for CD11b. Cells were then incubated with anti-human
antibodies. Using this analysis, three populations of RAW cells
were observed to develop over time. Initially, the RAW cells were
negative for both RTX and anti-human antibody (Figure 6A; DN
quadrant). Then over time a population arose that was positive for
both RTX and anti-human (Figure 6A, DP quadrant). This
represents trogocytic intermediates in which transfer but not
internalization of RTX has occurred; these may either be free
RAW cells that have detached a piece(s) of Ramos cells, or the
RAW cell halves of RAW-Ramos conjugates that are dissociated
in the process of detachment and resuspension of the RAW cells
(few if any conjugates remained intact after RAW detachment
(Figure S1A)). In either case, appearance of this population
represents a first step in which RTX becomes associated with the
RAW cell prior to its internalization. Finally, double-positive cells
disappeared and RTX single-positive cells appeared (Figure 6A,
SP quadrant), as RTX became internalized into the RAW cell and
was no longer accessible to the added anti-human antibody. Thus,
this analysis highlights that trogocytosis by macrophages can be
thought of as involving two sequential steps: conjugate formation
and antigen internalization.
Effects of chemical inhibitors on kinetics of trogocytosis
FcR-mediated phagocytosis requires extensive rearrangement of
the actin cytoskeleton triggered by Src family kinase-mediated
signalling downstream of receptor engagement [19]. Phosphati-
dylinositol 3 kinase (PI3K) is also required for engulfment of large
particles in a size-dependent manner, and acts to synthesize PIP3
at early stages of phagocytosis [20,21]. Both Src family-kinase
mediated protein phosphorylation and PIP3 levels are low in
unstimulated RAW264.7 cells [20,22]. To investigate the role of
these players in trogocytosis, we tested the effect of several
inhibitors, namely, cytochalasin D, an actin depolymerizing agent;
PP1, a Src family kinase inhibitor; and LY294002, a PI3K
inhibitor, at concentrations known to efficiently inhibit phosphor-
ylation or phagocytosis in RAW264.7 cells [4,21,22] (Figure 7).
For these experiments we pre-labelled Ramos cells with PKH26
Figure 3. Effect of treatment of Ramos cells with PAO on cell polarization and RTX accumulation at cell-cell interfaces. Opsonized
Ramos cells were treated with 30 mM PAO or DMSO vehicle for 10 min then washed. (A) Cell morphology and RTX distribution on live Ramos cells.
(B) Quantitation of effect of PAO on Ramos cell polarization. Images of live cells were acquired after treatment with PAO or DMSO, and the fraction of
total cells showing a polarized morphology at the moment of image acquisition was scored. Error bars show standard deviation (n=4 experiments,
with .300 cells scored per condition in each experiment (p,0.05)). (C) Comparison of RTX accumulation at the interfaces between RAW and Ramos
cells with or without pretreatment of Ramos cells with PAO. Deconvolved volumes and extended focus representations of target-trogocyte interfaces
are presented. Interfaces were imaged after 15 minutes of allowing cells to interact. Arrows indicate zones of contact between RAW and Ramos
(*) cells. Similar results were seen in 3 independent experiments. Scale bars 10 mm.
doi:10.1371/journal.pone.0014498.g003
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detachment of adherent cells were identified based on their high
staining for both PKH26 and anti-human (Figure S1D);
fortuitously, Ramos cells are strongly positive for anti-human
antibody staining even in the absence of RTX opsonization,
presumably due to recognition of surface Ig. We assessed the effect
of inhibitors on the fraction of RAW cells that moved out of the
DN population and on the kinetics of progression from DN to DP
to SP population. Cytochalasin D had the most profound effect,
largely blocking acquisition of RTX (Figure 7C), as was also
reported in previous studies of trogocytosis [12]. Though a small
proportion of cytochalasin D-treated RAW cells moved into the
SP population, these events failed to be PKH26 positive
(Figures 7E and S2), suggesting they represent either internaliza-
tion of only the most highly clustered RTX/CD20 complexes, or
alternatively internalization of RTX alone. PP1 also resulted in a
lower fraction of RAW cells responding, while LY294002 had little
if any effect on the fraction of responders (Figure 7C). Both PP1
and LY294002 led to a delay in acquisition of RTX, with an
increase in the half-time of movement from the DN to DP
population, suggestive of a defect in conjugate formation in the
presence of either inhibitor (Figure 7D). The inhibitors also all led
to reduced transfer of PKH26 to the RAW cells (Figure 7E).
Despite the delay in RTX acquisition, the cells still did eventually
progress to the SP population, suggesting that while Src family
kinases and PI3K are both required for optimal conjugate
formation, neither is essential for RTX internalization. Treatment
of Ramos cells on their own with PP1 or LY294002 did not affect
either cell polarization or RTX concentration at uropods,
suggesting that the effect of these inhibitors on trogocytosis was
due to their effects on the RAW cell, not on the targets (Figure 7F).
Cytochalasin D treatment did cause a large reduction in uropod
formation (Figure 7F), which may contribute to the inhibition of
trogocytosis (see below), though it is likely that the near-complete
inhibition of trogocytosis by cytochalasin D is primarily due to its
effect on the RAW cells.
Effects of blockade of uropod formation on trogocytosis
To assess the effect of polarization of target cells on the
efficiency of trogocytosis, we pre-treated Ramos cells with PAO
(followed by washing away PAO) to prevent formation of RTX-
rich uropods, as described above. As noted above, this treatment
led to reduced RTX concentration at sites of cell-cell contact
(Figure 3C). It also led to both a significant reduction in the
fraction of RAWs that are able to successfully engage Ramos and a
delay in the kinetics of RTX transfer (Figure 8). Taken together,
these results suggest that polarized concentration of antigen on a
target cell can facilitate the process of trogocytosis of that antigen.
Discussion
We observed a striking accumulation of CD20 at the uropod of
motile Ramos cells. CD20 has been shown to reside in ‘‘raft’’
microdomains by biochemical fractionation [23], or RTX
colocalization with cholera toxin subunit B staining [24], so it is
possible that its polarization is related to an association with
particular membrane subdomains. The polarization may be a
consequence of RTX binding/clustering, or alternatively may
occur even in the absence of RTX. These observations make the
important point that the mobility and distribution of a targeted
antigen in the cell membrane will likely be a key parameter in
determining the extent of trogocytosis. Polarized localization of
antigen may favour trogocytosis while conversely impairing or
even preventing complete phagocytosis of cells. FcR-mediated
phagocytosis proceeds by a ‘‘zippering’’ mechanism, in which
sequential engagement of Fc receptors by opsonizing antibody
drives pseudopods to extend around the particle. The absence of
opsonin on one side of a target prevents progression of pseudopod
extension [11,25]. In fact, the inability of macrophages to perform
phagocytosis of capped lymphocytes (where antibody-bound
surface Ig was polarized to one end of the lymphocyte) was a
key finding that provided an elegant and unambiguous proof of
the zipper hypothesis for phagocytosis [11]. In a similar manner,
the polarized localization of RTX/CD20 at the cell-cell interface
in our system may halt the circumferential extension of
pseudopods around the Ramos cell and, conversely, facilitate the
transfer of CD20/RTX complexes by trogocytosis, as suggested by
our findings of inhibition of trogocytosis when Ramos cells were
pretreated with PAO to prevent polarization. While trogocytosis
and phagocytosis can occur simultaneously under some conditions
[14], we never observed complete phagocytosis of Ramos by RAW
cells; this may be a consequence of CD20/RTX localization, or
alternatively may simply be a consequence of the relatively large
size of the Ramos – approximately 12 mm in diameter. Particle
shape is a key parameter constraining the efficiency of phagocy-
tosis [26,27]. Only certain geometries of the interface between
phagocyte and particle allow engulfment, which requires complex
localized changes in phosphoinositides and signalling proteins at
the phagocytic cup to orchestrate coordinated rearrangements of
the cytoskeleton [19]. When the ‘‘particle’’ engaged by a
macrophage is not inert (such a polystyrene bead) but rather a
dynamic cell that can change both its overall shape and the surface
distribution of opsonizing antibodies, clearly the phagocyte-target
interaction involves an even greater complexity. Accordingly, to
Figure 4. Distribution of trogocytosed RTX within RAW cells.
Acquired RTX-Al488 becomes widely distributed in RAW cells (*). Image
taken 70 minutes after the addition of RTX-Al488 coated Ramos. Scale
bar 10 mm. See Video S6.
doi:10.1371/journal.pone.0014498.g004
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the relative extent of these two processes, the characteristics of not
only the trogocyte but also of both the target antigen and cell
need to be considered. Recent work has demonstrated that certain
plasma membrane proteins are preferentially transferred to
lymphocytes by trogocytosis [28]. Similarly, the extent of
antibody-dependent trogocytosis of antigen by monocytes varies
for different antigens [13]. An important goal for future studies will
be defining the features of targeted antigens (e.g. mobility in the
plasma membrane) that influence trogocytosis. It will also be useful
to incorporate modulation of structural features of the target cell
such as membrane fluidity in these studies.
Our results with inhibitors implicate a role for cytoskeletal
rearrangements, Src family kinases, and PI3K signalling in the
optimal formation of cell-cell conjugates required for efficient
trogocytosis. In contrast to our results, Beum et al. did not observe
any effect of PP2 or wortmannin (also inhibitors of Src family
kinases and PI3K, respectively), on the overall efficiency of transfer
of RTX to THP-1 monocytes by trogocytosis [12]. One relevant
difference between the two sets of findings may be the particular
experimental configurations: in the THP-1 experiments, cells were
brought together by centrifugation, whereas in our setup, the
target cells come into contact with adherent RAW cells simply by
landing on or near them under the influence of gravity. In the
latter situation, the requirements for active pseudopod extension
by the RAW cells in order to form a robust conjugate may be
more stringent. This emphasizes that the trogocytosis process
measured in vitro will be highly dependent on the particular
experimental design. It is unclear what method of establishing cell-
cell contact best reflects the in vivo scenario, where trogocytosis is
likely to depend strongly on physical features of the local
physiological microenvironment such as shear stresses.
An advantage of our method of analysis by flow cytometry is
that it parses trogocytosis into two sequential steps: conjugate
formation and antigen internalization by the trogocyte. The initial
formation of cell-cell conjugates seems likely to involve many of
the same cytoskeletal and membrane rearrangements required for
phagocytosis of large particles, as is suggested by the effects of
inhibitors we observe (Figure 9). The subsequent internalization of
RTX from the target cells may also involve actin-driven force
generation. Alternatively, mobile antigens that can be concentrat-
ed into small clusters on the target cell membrane may allow for
Figure 5. Cotransfer of PKH26 and RTX. (A) Simultaneous acquisition of PKH26 and RTX-Al488 by RAW cells from Ramos cells was analyzed by
flow cytometry. (B) Lack of acquisition of PKH26 and RTX-Al488 by RAW cells after 45 minutes when opsonization of Ramos cells was omitted (no
RTX), or when RAW cells were provided with culture supernatants of RTX/PKH labelled Ramos cells incubated for the same amount of time (passive
transfer). (C) RAW cells that have internalized mainly RTX (green), or both RTX and PKH26 (yellow). Ramos cells indicated by asterisks. Scale bar 10 mm.
doi:10.1371/journal.pone.0014498.g005
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endocytosis of soluble immune complexes. Our observation of
trogocytosis in real time reveals that RTX is transferred in small
puncta rather than large fragments. Moreover, the fact that PP1
and LY294002, inhibitors of phagocytosis, do not prevent
internalization is consistent with an endocytic internalization
mechanism. Our preliminary findings also suggest that transfec-
tion of RAW cells with a dominant negative form of dynamin, a
GTPase required for membrane scission during FccR-mediated
endocytosis [4], inhibits trogocytic internalization of RTX (data
not shown). It would be interesting in the future to examine the
effect of specific perturbations of the endocytosis machinery, e.g.
knockdown of clathrin-coated pit components. It may be that
multiple internalization pathways are in fact initiated simulta-
neously, and which one predominates depends on several factors
such as opsonin density and the fluctuating geometry of the
particular cell-cell conjugate. More broadly, it is likely that the
transfer of membrane-bound antigens between cells can be
mediated by a variety of mechanisms; for instance, it has been
shown that B cells are able to acquire membrane-bound antigens
at 4uC, in contrast to T cells [18]. The requirement for conjugate
formation to occur prior to antigen internalization poses a
challenge for analyzing this second step of internalization in
isolation.
Figure 6. Kinetic analysis of acquisition and internalization of RTX by flow cytometry. Internalization of acquired RTX was assessed by its
inaccessibility to labelling with anti-human antibody. (A) RTX-Al488 coated Ramos cells were coincubated with RAW cells at 37uC for the times
indicated. After staining with anti-human antibody, RAW cells were detached and identified by gating on CD11b+ events. Bottom right plot shows a
schematic of the progression of RAW cells in the kinetic analysis of trogocytosis. Indicated numbers are percentage of events in each quadrant out of
the DN, DP, and SP populations. (B) The proportion of RAW cells in the DN population was fitted to a model as described in Methods. (C) Confocal
slices of cells representative of trogocytic stages. Scale bar 10 mm.
doi:10.1371/journal.pone.0014498.g006
Trogocytosis of Rituximab
PLoS ONE | www.plosone.org 7 January 2011 | Volume 6 | Issue 1 | e14498While trogocytosis by T cells can lead to prolonged exposure of
the trogocytosed antigen on the T cell surface [7,29], in the case of
macrophages, internalization of the removed antigen is likely the
rule [30]. Thus, the functional implications of FcR-driven
trogocytosis may relate not so much to macrophages gaining
novel surface proteins (and hence novel functions) as has been seen
with T and NK cells, but rather to its effects on the target cell.
Removal of CD20 from B cells limits the therapeutic efficiency of
RTX [31]. Conversely, for other antibodies the opposite may
conceivably be the case. For example, one could speculate that
removal of the growth-promoting Her2 receptor from breast
cancer cells via macrophage trogocytosis of trastuzumab/Her2
complexes might actually help to reduce tumour cell survival,
thereby enhancing the efficacy of trastuzumab. An additional
important consequence of trogocytosis is the concomitant
downregulation of FccR on the trogocytic cell [13]. This
downregulation may in fact account for the efficacy of RTX in
treatment of some autoimmune diseases, by inhibiting FccR-
driven pathological inflammation (the ‘‘immune complex decoy
hypothesis’’ [32]). Finally, trogocytosis may be a significant route
of uptake of antigen leading to ultimate presentation to T cells
[33]. For all these reasons, it will be important to determine both
the mechanisms within the trogocytosing cell that are involved in
antigen capture, as well as how the particular physical properties
of the antigen and target cell affect the efficiency of trogocytosis.
Materials and Methods
Cell lines and culture conditions
RAW264.7 (RAW) cells were obtained from the American
Type Culture Collection and maintained in DMEM with 10%
heat-inactivated fetal bovine serum (FBS) (Wisent, Quebec,
Canada). Cells were detached for subculturing or analysis by
scraping. Ramos cells, a human Burkitt’s B cell line, were
generously provided by Dr. Alberto Martin (University of
Toronto) and were maintained in IMDM (Gibco) + 10% FBS.
Figure 7. Kinetic analysis of chemical inhibition of trogocytosis. (A) Analysis of RTX transfer and internalization as in Figure 5 after 45 min of
trogocytosis in the presence of indicated inhibitors. cD, cytochalasin D. (B) Example kinetics of control versus PP1-inhibited trogocytosis.
(C) Comparison of percent responding RAW cells under different conditions. Linked pairs indicate individual experiments. Braces indicate significance
(p,0.05), n=3 for each control-inhibitor pair. For cytochalasin D experiments, percent responding RAW cells (control and cytochalasin D-treated) are
indicated by the percent responding at 90 minutes rather than the modelled asymptote. (D) Comparison of time to half-response under different
conditions. (E) Effect of inhibitors on acquisition of PKH26 at 90 minutes relative to media-treated RAW cells. Error bars indicate standard deviation,
n=3 for each treatment. (F) Effect of inhibitors on Ramos cell polarization (black bars) and concentration of RTX at uropods (white bars). Error bars
indicate standard deviation. Only cytochalasin D causes significant inhibition (p,0.05, n=4).
doi:10.1371/journal.pone.0014498.g007
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Reagents
Rituximab (RTX) was a generous gift from Dr. David Spaner
(Sunnybrook Research Institute, Ontario, Canada) and was
conjugated using an Alexa Fluor 488 Protein Labelling Kit
(Invitrogen). Rat anti-mouse CD11b-PE/APC (clone M1/80) was
obtained from the Sunnybrook Research Institute antibody
facility, BD Pharmingen, or Biolegend and used as directed.
Donkey anti-human DyLight 649 (DL649) antibody was obtained
from Jackson ImmunoResearch. PP1 was from Biomol. LY294002
was from Calbiochem. Cytochalasin D, PKH26, dimethylsulfoxide
(DMSO) and PAO were from Sigma.
Preparation of cells for trogocytosis
Ramos cells were opsonized with Alexa Fluor-488-conjugated
RTX (RTX-Al488) for 20 minutes with agitation at 37uC. RTX-
Al488 was used at a saturating concentration of 0.3 mg per 10
6
Ramos cells. In some experiments, Ramos cells were labelled with
PKH26 according to manufacturer’s instructions. Chemical
inhibitors of internalization were used at 10 mM cytochalasin D,
30 mM PP1, or 50 mM LY294002, by incubation of RAW cells at
37uC for 30 minutes in RAW medium with serum immediately
prior to the trogocytosis assay. 0.5% DMSO was used as a vehicle
control. After adding RTX-Al488 coated Ramos cell suspensions
to RAW cells, chemical inhibitors were restored to their
appropriate concentrations. For PAO pretreatment of Ramos
cells, cells were incubated with 30 mM PAO for 10 minutes, then
washed twice to remove PAO before addition to RAW cells.
Live microscopy of trogocytosis
RAWcells (1610
6cells) were seeded on 25 mm diametercoverglass
(Fisher Scientific), cultured overnight, then mounted in an Attofluor
chamber (Molecular Probes) followed by imaging on a 37uC heated
stage. RAW cell media was replaced with phenol red-free HEPES-
buffered RPMI (HPMI) with serum (Wisent). Ramos cells (1610
6 cells)
were labelled with PKH26 (in some experiments), coated with RTX-
Al488, resuspended in HPMI and laid over RAW cells. Epifluorescent
microscope images were acquired with a Hamamatsu ORCA camera
attached to a Zeiss Axiovert 200M microscope, with 4061.3NA oil
and 10061.4NA oil objectives. Alternatively, scanning confocal
microscope images were acquired with a Zeiss LSM 510 with a
6361.2NA water objective. Time lapse data was generated by imaging
at 30s intervals. Care was taken to minimize exposure time for each
field of view to reduce photobleaching and phototoxicity. Data were
analyzed with AxioVision (Zeiss) and Volocity (Improvision) software
packages. For observation of Ramos cell motility, cells were viewed
either on cover glass on which RAW cells had been cultured, or on
cover glass pre-incubated with RAW media (DMEM with 10% FBS),
since Ramos cells adhered and spread irreversibly when plated on fresh
cover glass in serum-free conditions. Ramos cell polarization was
scored by observation of lamellipodial extensions by differential
interference contrast microscopy.
Flow cytometry-based trogocytosis assay
Ramos cells were labelled with the fluorescent lipid dye PKH26
(in some experiments), then opsonized with RTX-Al488. RAW
cells were seeded in 6 well plates (10
6 cells/well) and cultured
overnight. RAW cells were treated with appropriate chemical
inhibitors for 30 minutes at 37uC and then cooled to 4uC. RAW
medium was then replaced with Ramos cell suspensions,
supplementing inhibitors where necessary. Ramos cells (2–4610
6
cells per well) were provided to obtain a 2:1 target: trogocyte ratio
and were allowed to settle onto RAW cells for 10 minutes at 4uC.
Trogocytosis was initiated by moving cells to a 37uC5 %C O 2
incubator, and stopped by moving cell mixtures to 4uC.
Remaining surface-bound rituximab on RAW cells was labelled
with DL649-conjugated anti-human antibody (0.6 mg per 10
6 cells)
at 4uC for 10 minutes. Adherent cells were washed once with PBS.
In some experiments, adherent cells were stained with fluoro-
phore-conjugated CD11b at 4uC for 10 minutes and washed
again. Adherent cells were then scraped, resuspended in PBS, and
fixed with 2% paraformaldehyde prior to flow cytometry.
Flow cytometry kinetic analysis
The RAW population in the detached adherent cells was
analyzed for the acquisition and internalization of RTX. Cells
Figure 8. Effect of pre-treatment of Ramos cells with PAO on
trogocytosis. Ramos cells were pretreated with 30 mM PAO for 10 min
and washed before addition to RAW cells. Trogocytosis of RTX was
analyzed by flow cytometry for percent responding RAW cells and time
to half-response. Linked pairs indicate individual experiments. Braces
indicate significant difference (p,0.05, n=4).
doi:10.1371/journal.pone.0014498.g008
Figure 9. Trogocytosis may involve components of both the
phagocytosis and endocytosis machinery.
doi:10.1371/journal.pone.0014498.g009
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which identifies both RAW and residual Ramos cells. RAW cells
were identified by CD11b positivity or by excluding Ramos cells as
events high in both PKH26 and anti-human DL649 (Figure S1).
RAW cell events were analyzed by an external RTX (anti-
human) versus total RTX plot. Quadrants were drawn according
to the 0 minute condition to define a double negative (DN)
population, and infer a double positive (DP) population and total
RTX single positive (SP) population (See Figure 6A). These
represent populations of RAW trogocytic intermediates and RAW
cells that have trogocytosed and internalized RTX, respectively.
Spillover events in the top left quadrant were not considered in the
analysis. The exit of DN events into the DP population for
conditions without chemical inhibitors was modelled by the
exponential decay function
DNctrl t ðÞ ~Ae{btz 100{A ðÞ ð 1Þ
where A reflects the final proportion of RAW cells that respond
(acquire RTX), and b, a rate constant. For chemical inhibition
experiments (in which delay of transition to DP population was
seen), the DN population was modelled by the sigmoidal function
DNinhib t ðÞ ~100{a 1ze{b t{c ðÞ
 {1
ð2Þ
where a represents the proportion of responding RAW cells, b, the
rate constant, and c the time required for half of the responding
RAW cells to respond. Coefficients were determined by least-
squares analysis by Excel’s Solver function. A two-tailed paired
Student’s t-test was used to determine significance of differences
between chemically-inhibited and control conditions.
Supporting Information
Figure S1 Gating strategies for distinguishing RAW and Ramos
cells. RAW and Ramos cells were incubated for 10 min to allow
conjugates to form, then adherent cells were washed, detached and
processed for flow cytometry. (A) Intact RAW-Ramos conjugates
did not persist after cell processing. While a population of RAW
cells acquired anti-human staining, very few show staining
equivalent in total fluorescence to Ramos cells, as would be
expected for cell-cell conjugates (dotted box). (B) Cells were stained
with anti-CD11b-PE to distinguish RAW cells from Ramos. (C)
RTX and anti-human staining analysis with CD11b+ RAW cells
shown in blue and CD11b- Ramos in red, showing distinct
populations. (D) Alternative gating strategy used in experiments
where Ramos cells were PKH-labelled. Ramos cells were
identified based on high staining with anti-human and PKH
(shaded gate). (E) RTX and anti-human staining analysis with
RAW and Ramos gated as in (D) in blue and red, respectively,
showing populations similar to those seen with CD11b staining.
Found at: doi:10.1371/journal.pone.0014498.s001 (9.25 MB TIF)
Figure S2 Transfer of membrane is inhibited by cytochalasin D.
PKH26 labelled, RTX-Al488 coated Ramos cells were coin-
cubated with RAW cells for the times indicated. Co-transfer of
RTX-Al488 and PKH26 occurs in the absence of cytochalasin D
(top row). After treatment with cytochalasin D (bottom row),
transfer is reduced, limited to RTX only, and observed only late in
the reaction.
Found at: doi:10.1371/journal.pone.0014498.s002 (4.32 MB TIF)
Video S1 Ramos morphology and RTX localization. Reversible
changes in morphology coincide with the enrichment of RTX-Al488
(green) at the cell-substrate interface. Opposite the uropod, extensive
membrane projections are observed. Scale bar 10 mm. Images
acquired every 30s, played at 15fps (4506RT). Total time: 30 min.
Found at: doi:10.1371/journal.pone.0014498.s003 (0.38 MB
MP4)
Video S2 Ramos mobility. Live time lapse microscopy 90 minutes
after the addition of RTX-Al488 (green) coated Ramos cells to RAW
cells. A Ramos cell is shown moving along the glass surface while
dynamically changing morphology. Asterisks indicate RAW cells
performing trogocytosis of captured Ramos.Scalebar 10 mm. Images
acquired every 30s, played at 15fps (4506RT). Total time: 30 min.
Found at: doi:10.1371/journal.pone.0014498.s004 (2.29 MB
MP4)
Video S3 Uropod capture and trogocytosis at the RAW-uropod
interface. Movie of live microscopy experiment shown in
Figure 2A. RTX-Al488 (green) labeled Ramos cells were
incubated with RAW cells. Scale bar 10 mm. Images acquired
every 30s, played at 15fps (4506RT). Total time: 29.5 min.
Found at: doi:10.1371/journal.pone.0014498.s005 (1.24 MB
MP4)
Video S4 Capture of Ramos cells and RTX-Al488 enrichment
at interface. RTX-Al488 (green) labelled Ramos cells were
incubated with RAW cells. Scale bar 10 mm. Images acquired
every 30s, played at 15fps (4506RT). Total time: 30 min.
Found at: doi:10.1371/journal.pone.0014498.s006 (1.51 MB
MP4)
Video S5 Multiple Ramos captured by a single RAW cell. RAW
cells (*) are able to trogocytose from many Ramos cells at once.
RTX-depleted mobile end of Ramos cell was not captured by
RAW (red arrow). Time lapse taken 30 min after the addition of
RTX-Al488 coated Ramos cells to RAW cells. Scale bar 10 mm.
Images acquired every 30s, played at 15fps (4506RT). Total time:
30 min.
Found at: doi:10.1371/journal.pone.0014498.s007 (1.02 MB
MP4)
Video S6 Streaming of trogocytosed RTX. Movement of
trogocytosed RTX within RAW cells 1–1.5 hr after the addition
of RTX-Al488 coated Ramos to RAW cells. Fading of
fluorescence signal occurs as a result of photobleaching. Scale
bar 10 mm. Images acquired every 30s, played at 15fps (4506RT).
Total time: 30 min.
Found at: doi:10.1371/journal.pone.0014498.s008 (2.57 MB
MP4)
Video S7 RAW cells after trogocytosis. Live microscopy imaging
1 hr after addition of RTX-Al488 coated Ramos cells to RAW
cells. RTX has collected in large vacuolar compartments in many
cells. Scale bar 10 mm. Images acquired every 30s, played at 15fps
(4506RT). Total time: 5 min.
Found at: doi:10.1371/journal.pone.0014498.s009 (6.12 MB
MP4)
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